Immune-associated pneumonitis caused by sintilimab
10.3760/cma.j.cn114015-20220615-00530
- VernacularTitle:信迪利单抗致免疫相关性肺炎
- Author:
Fenfang WANG
1
;
Jingya BAO
1
;
Qihuan WU
1
Author Information
1. 浙江省象山县第一人民医院医疗健康集团肿瘤内科，宁波 315700
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Lung diseases, interstitial;
Sintilimab;
Immune-associated pneumonitis
- From:
Adverse Drug Reactions Journal
2023;25(3):190-192
- CountryChina
- Language:Chinese
-
Abstract:
A 56-year-old male patient with nasopharyngeal carcinoma had progressed disease after receiving radiotherapy, chemotherapy, and targeted therapy, etc. Then he received chemotherapy combined with immunotherapy (capecitabine and sintilimab). Before receiving the 3rd immunotherapy, no abnormality was found in the relevant examination in the patient. On the 3rd day of treatment, he developed cough, shortness of breath, and other symptoms, and chest CT imaging indicated inflammatory lesion of both lungs. The results of sputum culture, sputum smear examination, G test, GM test, and autoantibody examination were all negative. Infectious pneumonia and interstitial pneumonia with autoimmune features were excluded. The common respiratory adverse reaction to capecitabine was pharyngeal discomfort, and no large-scale pneumonia caused by capecitabine was reported. Therefore, it was considered to be immune-associated pneumonitis cause by sintilimab. Treatments such as intravenous injection of methylprednisolone, IV infusion of cefoperazone sodium and sulbactam sodium and moxifloxacin were given and the patient′s condition was improved. After that, methylprednisolone dose was gradually reduced, and then changed to oral prednisone. On the 10th day of oral prednisone, the symptom of shortness of breath worsened. Chest CT imaging indicated that the pneumonitis was more severe than before. Intravenous methylprednisolone was re-given but the condition was not improved.
